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Background
The membrane proximal external region (MPER) of the
HIV-1 envelope is recognized by three of the few broadly
cross-neutralizing antibodies described so far. Recent
studies have reported anti-MPER antibodies in plasmas
from some HIV-infected individuals with broadly cross-
neutralizing activity. Here we followed the evolution of
anti-MPER antibodies in an individual that developed
broad neutralization.
Methods
Multiple plasma samples from participant CAP206 from
pre-seroconversion to 3 years post-infection were tested
for heterologous neutralization against 42 viruses from
various subtypes and HIV-2/HIV-1 MPER chimeric
viruses. Envelope clones were generated at 2-weeks (trans-
mitted virus), 2-, 6-, 12- and 21-months post-infection by
single genome amplification and used in neutralization
assays. Anti-MPER antibodies were depleted from plasma
by adsorption onto MPER-peptide-coated beads and
tested in anti-MPER ELISA and neutralization assays.
Results
Antibodies able to mediate autologous neutralization of
the transmitted virus developed at 8-weeks post-infection.
Neutralization escape occurred rapidly with envelope
clones from 2-months post-infection showing reduced
neutralization sensitivity compared to the transmitted
variant. Anti-MPER antibodies were detected at 22-weeks
post-infection using the HIV-1/HIV-2 chimera C1C, how-
ever this participant did not show neutralization breadth
at this time-point. At 81-weeks these anti-MPER antibod-
ies became independent of W670 for neutralization. This
change in specificity corresponded with the emergence of
antibodies able to neutralize 18 viruses. Depletion of anti-
MPER antibodies using peptide-coated magnetic beads
removed this heterologous activity. Anti-MPER antibodies
eluted from the beads also neutralized the early autolo-
gous virus.
Conclusion
We described the evolution of a cross-neutralizing anti-
MPER antibody response and its relationship to the autol-
ogous response. Our data suggest that affinity maturation
of the anti-MPER antibodies may have resulted in neutral-
ization breadth. Further study of the evolution of these
antibodies and characterization of the virus quasispecies
in this individual may provide useful information for the
design of vaccine immunogens that induce anti-MPER
antibodies.
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